Examkin

Soru

Zorluk: ZorRheumatology and Immunology

Match the following rheumatologic autoantibodies with their most characteristic clinical phenotypes and prognostic associations.

  • Anti-topoisomerase I (anti-Scl-70) antibodiesAssociated with diffuse cutaneous systemic sclerosis and a significant risk for rapidly progressive interstitial lung disease.
  • Anti-centromere antibodiesAssociated with limited cutaneous systemic sclerosis and a heightened risk for isolated pulmonary arterial hypertension.
  • Anti-histidyl-tRNA synthetase (anti-Jo-1) antibodiesAssociated with an inflammatory myopathy syndrome featuring interstitial lung disease, nonerosive arthritis, and hyperkeratotic skin changes on the hands.
  • Anti-U1-ribonucleoprotein (RNP) antibodiesRequired for the diagnosis of mixed connective tissue disease, which classically presents with overlapping features of lupus, systemic sclerosis, and polymyositis.
  • Anti-Ro/SSA and Anti-La/SSB antibodiesAssociated with Sjögren syndrome and carries a significant risk of transmitting congenital heart block to the neonate in pregnant patients.

Cevap

The correct matches align specific autoantibodies with their prognostic risks: Anti-Scl-70 with diffuse systemic sclerosis (ILD risk); Anti-centromere with limited systemic sclerosis (PAH risk); Anti-Jo-1 with antisynthetase syndrome; Anti-U1-RNP with mixed connective tissue disease; and Anti-Ro/La with Sjögren syndrome and neonatal lupus.
Each specific autoantibody in rheumatology serves not just as a diagnostic marker, but as a prognostic indicator for specific organ involvement and disease complications. Recognizing these associations is essential for appropriate patient monitoring (e.g., screening echocardiograms for PAH in anti-centromere patients, high-resolution CT for ILD in anti-Scl-70 patients, and fetal echocardiography in anti-Ro positive pregnant women).

Adım Adım Çözüm

1
Analyze the systemic sclerosis autoantibodies.
Identify that anti-topoisomerase I (anti-Scl-70) correlates with diffuse disease and interstitial lung disease, while anti-centromere correlates with limited disease and pulmonary arterial hypertension.
Differentiating the systemic sclerosis subtypes is critical for anticipating and screening for fatal visceral complications.
2
Evaluate the myopathy-associated antibody.
Match anti-Jo-1 to the syndrome featuring myositis, interstitial lung disease, and 'mechanic's hands'.
Anti-Jo-1 characterizes antisynthetase syndrome, a distinct subset of inflammatory myopathies where lung disease drives mortality.
3
Identify the defining antibody for overlap syndromes.
Match anti-U1-RNP to mixed connective tissue disease.
MCTD is defined serologically by the presence of anti-U1-RNP in the setting of overlapping clinical features.
4
Assess the reproductive risks of sicca syndrome antibodies.
Match Anti-Ro/SSA and Anti-La/SSB to Sjögren syndrome and the risk of neonatal heart block.
These IgG antibodies can cross the placenta, bind to fetal cardiac tissue, and permanently damage the developing atrioventricular node.

Anahtar Kavram

Autoantibody profiles in connective tissue diseases dictate clinical phenotypes, visceral organ involvement, and specific prognostic complications.
Tahmini Süre:1m 0s
Bu soruyu puanla

Konular

Rheumatology and Immunology

Bu konudan daha fazla soru